The brain has plans in place when fires break out. Normally, a molecule called PKD1 rushes in to the rescue, but in ...

To date, the GeM-HD consortium has studied thousands of people with HD and hundreds of thousands of spelling changes in every ...

Spark Therapeutics, recently integrated into Roche Pharmaceuticals, has been working on an HD gene therapy. It’s delivered via a one-time brain surgery and is designed to lower levels of the ...

TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation ...

The HDBuzz editorial team had a virtual sit-down with HDBuzz founder, editor emeritus, Huntington’s disease (HD) researcher, and neurologist Professor Ed Wild. We laughed, we cried… actually we just ...

DNA-based drugs called antisense oligonucleotides, or ASOs, are now in multiple clinical trials in Huntington’s disease, aiming to lower production of the harmful mutant huntingtin protein in the ...

Support HDBuzz Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community ...

Last month, we relayed positive news from uniQure’s trial testing AMT-130, a gene therapy delivered via brain surgery to lower huntingtin (HTT). Data released by uniQure in June suggested AMT-130 was ...

As we wave goodbye to 2024, the HDBuzz team reflects on a year marked by significant progress, challenges, and hope. From breakthroughs at the lab bench, advancements in drug development, and both ...